Literature DB >> 26438454

Emergency Neurological Life Support: Pharmacotherapy.

Gretchen M Brophy1, Theresa Human2, Lori Shutter3.   

Abstract

The appropriate use of medications during Emergency Neurological Life Support (ENLS) is essential to optimize patient care. Important considerations when choosing the appropriate agent include the patient's organ function and medication allergies, potential adverse drug effects, drug interactions, and critical illness and aging pathophysiologic changes. Critical medications used during ENLS include hyperosmolar therapy, anticonvulsants, antithrombotics, anticoagulant reversal and hemostatic agents, anti-shivering agents, neuromuscular blockers, antihypertensive agents, sedatives, vasopressors and inotropes, and antimicrobials. This article focuses on the important pharmacokinetic and pharmacodynamics characteristics, advantages and disadvantages, and clinical pearls of these therapies, providing practitioners with essential drug information to optimize pharmacotherapy in acutely ill neurocritical care patients.

Entities:  

Keywords:  Adverse drug event; Drug interaction; ENLS; Medication; Pharmacotherapy

Mesh：

Year:  2015        PMID： 26438454     DOI： 10.1007/s12028-015-0158-1

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN： 1541-6933            Impact factor:   3.532


  53 in total

1.  Variability in platelet responsiveness to clopidogrel among 544 individuals.

Authors:  Victor L Serebruany; Steven R Steinhubl; Peter B Berger; Alex I Malinin; Deepak L Bhatt; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

Review 2.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Corticosteroids for acute bacterial meningitis.

Authors:  D van de Beek; J de Gans; P McIntyre; K Prasad
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.

Authors:  Lorne Holland; Theodore E Warkentin; Majed Refaai; Mark A Crowther; Marilyn A Johnston; Ravindra Sarode
Journal:  Transfusion       Date:  2009-02-06       Impact factor: 3.157

5.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

6.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

7.  Osmolality not predictive of mannitol-induced acute renal insufficiency.

Authors:  Francisco de Assis Aquino Gondim; Venkatesh Aiyagari; Angela Shackleford; Michael N Diringer
Journal:  J Neurosurg       Date:  2005-09       Impact factor: 5.115

8.  Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage.

Authors:  Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

9.  Predictors and clinical implications of shivering during therapeutic normothermia.

Authors:  Neeraj Badjatia; Robert G Kowalski; J Michael Schmidt; Marc E Voorhees; Jan Claassen; Noeleen D Ostapkovich; Mary Presciutti; E Sander Connolly; David Palestrant; Augusto Parra; Stephan A Mayer
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Continuous controlled-infusion of hypertonic saline solution in traumatic brain-injured patients: a 9-year retrospective study.

Authors:  Antoine Roquilly; Pierre Joachim Mahe; Dominique Demeure Dit Latte; Olivier Loutrel; Philippe Champin; Christelle Di Falco; Athanase Courbe; Kevin Buffenoir; Olivier Hamel; Corinne Lejus; Véronique Sebille; Karim Asehnoune
Journal:  Crit Care       Date:  2011-10-28       Impact factor: 9.097
View more
  6 in total

1.  Effects of Osmotic Therapy on Pupil Reactivity: Quantification Using Pupillometry in Critically Ill Neurologic Patients.

Authors:  C Ong; M Hutch; M Barra; A Kim; S Zafar; S Smirnakis
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

Review 2.  Neurocritical care update.

Authors:  Yasuhiro Kuroda
Journal:  J Intensive Care       Date:  2016-05-28

3.  Erratum to: Neurocritical care update.

Authors:  Yasuhiro Kuroda
Journal:  J Intensive Care       Date:  2016-07-25

4.  Autoimmune Encephalitis at the Neurological Intensive Care Unit: Etiologies, Reasons for Admission and Survival.

Authors:  Gayane Harutyunyan; Larissa Hauer; Martin W Dünser; Anush Karamyan; Tobias Moser; Slaven Pikija; Markus Leitinger; Helmut F Novak; Eugen Trinka; Johann Sellner
Journal:  Neurocrit Care       Date:  2017-08       Impact factor: 3.210

5.  The Benefit of Neuromuscular Blockade in Patients with Postanoxic Myoclonus Otherwise Obscuring Continuous Electroencephalography (CEEG).

Authors:  Christopher R Newey; Alejandro Hornik; Meziane Guerch; Anantha Veripuram; Sushma Yerram; Agnieszka Ardelt
Journal:  Crit Care Res Pract       Date:  2017-02-06

6.  Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.

Authors:  Jessica L Corio; Jonathan H Sin; Bryan D Hayes; Joshua N Goldstein; Lanting Fuh
Journal:  West J Emerg Med       Date:  2018-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.